Header Logo

Connection

MARTIN KORBLING to Transplantation, Homologous

Back to Details
This is a "connection" page, showing publications MARTIN KORBLING has written about Transplantation, Homologous.
MARTIN KORBLING
Connection Strength
1.347
Transplantation, Homologous
  1. Collection of allogeneic peripheral blood stem cells. Baillieres Best Pract Res Clin Haematol. 1999 Mar-Jun; 12(1-2):41-55.
    View in: PubMed
    Score: 0.109
  2. Allogeneic peripheral blood stem cell transplantation for hematologic diseases. Cancer Treat Res. 1999; 101:1-23.
    View in: PubMed
    Score: 0.107
  3. Allogeneic blood stem cell transplantation: considerations for donors. Blood. 1997 Aug 01; 90(3):903-8.
    View in: PubMed
    Score: 0.097
  4. The use of mobilized peripheral blood stem cells from normal donors for allografting. Stem Cells. 1997; 15(1):9-17.
    View in: PubMed
    Score: 0.093
  5. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood. 2004 Aug 01; 104(3):857-64.
    View in: PubMed
    Score: 0.039
  6. Extracorporeal photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation: feasibility and results. Bone Marrow Transplant. 2003 Mar; 31(6):459-65.
    View in: PubMed
    Score: 0.036
  7. Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma. Bone Marrow Transplant. 2002 Sep; 30(6):367-73.
    View in: PubMed
    Score: 0.035
  8. Peripheral blood stem cell versus bone marrow allotransplantation: does the source of hematopoietic stem cells matter? Blood. 2001 Nov 15; 98(10):2900-8.
    View in: PubMed
    Score: 0.033
  9. Donor lymphocyte apheresis for adoptive immunotherapy compared with blood stem cell apheresis. J Clin Apher. 2001; 16(2):82-7.
    View in: PubMed
    Score: 0.031
  10. A comparative study of once-daily versus twice-daily filgrastim administration for the mobilization and collection of CD34+ peripheral blood progenitor cells in normal donors. Br J Haematol. 2000 Jun; 109(4):770-2.
    View in: PubMed
    Score: 0.030
  11. Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. Blood. 1999 Aug 15; 94(4):1465-70.
    View in: PubMed
    Score: 0.028
  12. Thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced chronic myelogenous leukemia. Bone Marrow Transplant. 1999 May; 23(10):977-81.
    View in: PubMed
    Score: 0.027
  13. Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma. Ann Oncol. 1999 May; 10(5):527-32.
    View in: PubMed
    Score: 0.027
  14. Allogeneic peripheral blood stem cell transplantation for active hemophagocytic lymphohistiocytosis. Bone Marrow Transplant. 1998 Aug; 22(3):301-2.
    View in: PubMed
    Score: 0.026
  15. Blood stem cell procurement: donor safety issues. Bone Marrow Transplant. 1998 Jun; 21 Suppl 3:S35-9.
    View in: PubMed
    Score: 0.026
  16. Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. J Clin Oncol. 1998 Mar; 16(3):986-93.
    View in: PubMed
    Score: 0.025
  17. Identification of megakaryocyte precursors in peripheral blood stem cell collections from normal donors. J Clin Apher. 1998; 13(1):7-15.
    View in: PubMed
    Score: 0.025
  18. Toxicities of tacrolimus and cyclosporin A after allogeneic blood stem cell transplantation. Bone Marrow Transplant. 1997 Dec; 20(12):1095-8.
    View in: PubMed
    Score: 0.025
  19. Allogeneic blood or marrow transplantation for chronic lymphocytic leukaemia: timing of transplantation and potential effect of fludarabine on acute graft-versus-host disease. Br J Haematol. 1997 May; 97(2):466-73.
    View in: PubMed
    Score: 0.024
  20. Collection of peripheral blood stem cells from normal donors 60 years of age or older. Br J Haematol. 1997 May; 97(2):485-7.
    View in: PubMed
    Score: 0.024
  21. Allogeneic blood stem cell transplantation in advanced hematologic cancers. Bone Marrow Transplant. 1997 Mar; 19(5):455-60.
    View in: PubMed
    Score: 0.024
  22. Allogeneic transplantation for advanced leukemia: improved short-term outcome with blood stem cell grafts and tacrolimus. Transplantation. 1996 Dec 27; 62(12):1806-10.
    View in: PubMed
    Score: 0.023
  23. Delayed effects of rhG-CSF mobilization treatment and apheresis on circulating CD34+ and CD34+ Thy-1dim CD38- progenitor cells, and lymphoid subsets in normal stem cell donors for allogeneic transplantation. Bone Marrow Transplant. 1996 Dec; 18(6):1073-9.
    View in: PubMed
    Score: 0.023
  24. Allogeneic peripheral blood stem cell transplantation using normal patient-related pediatric donors. Bone Marrow Transplant. 1996 Nov; 18(5):885-90.
    View in: PubMed
    Score: 0.023
  25. Allogeneic blood stem cell transplantation: the US experience. Hematol Cell Ther. 1996 Oct; 38(5):456-7.
    View in: PubMed
    Score: 0.023
  26. Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation. Cancer. 2016 Nov 15; 122(21):3316-3326.
    View in: PubMed
    Score: 0.023
  27. Duration of filgrastim mobilization and apheresis yield of CD34+ progenitor cells and lymphoid subsets in normal donors for allogeneic transplantation. Br J Haematol. 1996 Jun; 93(4):940-2.
    View in: PubMed
    Score: 0.022
  28. Peripheral blood progenitor cell transplantation: a replacement for marrow auto- or allografts. Stem Cells. 1996 Mar; 14(2):185-95.
    View in: PubMed
    Score: 0.022
  29. Are CD34+ selected cells the better choice for grafting? Cancer Invest. 1996; 14(6):640-1.
    View in: PubMed
    Score: 0.022
  30. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood. 1995 Dec 01; 86(11):4337-43.
    View in: PubMed
    Score: 0.022
  31. Allogeneic blood stem cell transplantation: peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+ Thy-1dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease. Blood. 1995 Oct 01; 86(7):2842-8.
    View in: PubMed
    Score: 0.021
  32. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood. 1995 Mar 15; 85(6):1659-65.
    View in: PubMed
    Score: 0.021
  33. BFR (bendamustine, fludarabine, and rituximab) allogeneic conditioning for chronic lymphocytic leukemia/lymphoma: reduced myelosuppression and GVHD. Blood. 2014 Oct 02; 124(14):2306-12.
    View in: PubMed
    Score: 0.020
  34. Allogeneic stem cell transplant in patients with chronic lymphocytic leukemia with 17p deletion: consult-transplant versus consult- no-transplant analysis. Leuk Lymphoma. 2015 Mar; 56(3):711-5.
    View in: PubMed
    Score: 0.020
  35. Cord-blood engraftment with ex vivo mesenchymal-cell coculture. N Engl J Med. 2012 Dec 13; 367(24):2305-15.
    View in: PubMed
    Score: 0.018
  36. Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results. Blood. 2012 Jun 28; 119(26):6373-8.
    View in: PubMed
    Score: 0.017
  37. Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT. Bone Marrow Transplant. 2010 Mar; 45(3):429-36.
    View in: PubMed
    Score: 0.014
  38. Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. Biol Blood Marrow Transplant. 2008 Jun; 14(6):672-84.
    View in: PubMed
    Score: 0.013
  39. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood. 2008 Jun 15; 111(12):5530-6.
    View in: PubMed
    Score: 0.013
  40. Graft-versus-leukaemia effect after non-myeloablative haematopoietic transplantation can overcome the unfavourable expression of ZAP-70 in refractory chronic lymphocytic leukaemia. Br J Haematol. 2007 May; 137(4):355-63.
    View in: PubMed
    Score: 0.012
  41. Transplant-associated microangiopathy in patients receiving tacrolimus following allogeneic stem cell transplantation: risk factors and response to treatment. Biol Blood Marrow Transplant. 2007 Apr; 13(4):469-77.
    View in: PubMed
    Score: 0.012
  42. Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival. Exp Hematol. 2004 Jan; 32(1):28-35.
    View in: PubMed
    Score: 0.009
  43. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood. 2001 Dec 15; 98(13):3595-9.
    View in: PubMed
    Score: 0.008
  44. Decitabine with allogeneic peripheral blood stem cell transplantation in the therapy of leukemia relapse following a prior transplant: results of a phase I study. Bone Marrow Transplant. 2001 Jun; 27(12):1221-5.
    View in: PubMed
    Score: 0.008
  45. Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation. Biol Blood Marrow Transplant. 2001; 7(10):568-75.
    View in: PubMed
    Score: 0.008
  46. Early detection of relapse by hypermetaphase fluorescence in situ hybridization after allogeneic bone marrow transplantation for chronic myeloid leukemia. J Clin Oncol. 2000 May; 18(9):1831-6.
    View in: PubMed
    Score: 0.007
  47. Allogeneic hematopoietic transplantation for mantle-cell lymphoma: molecular remissions and evidence of graft-versus-malignancy. Ann Oncol. 1999 Nov; 10(11):1293-9.
    View in: PubMed
    Score: 0.007
  48. Albumin density gradient purification of canine hemopoietic blood stem cells (HBSC): long-term allogeneic engraftment without GVH-reaction. Exp Hematol. 1979 Jul; 7(6):277-88.
    View in: PubMed
    Score: 0.007
  49. Allogeneic transplantation for recurrent or refractory non-Hodgkin's lymphoma with poor prognostic features after conditioning with thiotepa, busulfan, and cyclophosphamide: experience in 44 consecutive patients. Biol Blood Marrow Transplant. 1997 Aug; 3(3):150-6.
    View in: PubMed
    Score: 0.006
  50. Bone marrow transplantation after failure of autologous transplant for non-Hodgkin's lymphoma. Bone Marrow Transplant. 1997 Jan; 19(2):121-7.
    View in: PubMed
    Score: 0.006
  51. Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: the case for aggressive management. J Clin Oncol. 1995 May; 13(5):1096-102.
    View in: PubMed
    Score: 0.005
  52. Specific absorbed antithymocyte globulin for incubation treatment in human marrow transplantation. Transplant Proc. 1977 Mar; 9(1):187-91.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.